TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review Abstract Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Benatar
Repairing the Amyotrophic Lateral Sclerosis Trial Credibility Gap
Contemporary Issues in Practice, Education, & Research Open Access “You take the blue pill—the story ends, you wake up in your bed and believe whatever you want to believe.
Management of Exacerbations and Rescue Therapy : A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial
|
By Richard J. Nowak, Kimiaki Utsugisawa, Michael Benatar, Emma Ciafaloni, M. Isabel Leite, John Vissing, Fengming Tang, Yanping Wu, Catherine E Najem, Sue Cheng, James Howard, Conrado J. Estol, Florencia Aguirre, Alexandre Guerreiro, WIlson Marques Júnior, Wilson Marques Junior, Vera Bril, Xinghu Zhang, Dian He, Lan Chu, Chongbo Zhao, Yuwei Da, Qi Fang, Jing Li, Ting Chang, Sabrina Sacconi, Aleksandra Nadaj-Pakleza, Tim Hagenacker, Praveen Kumar S, Jayantee Kalita, Rukmini M. Kandadai, Neeharika L Mathukumalli, Raffaele Iorio, Renato Mantegazza, Carlo Antozzi, Akiyuki Uzawa, Yasushi Suzuki, Masako Suzuki, Takayuki Kondo, Anetta Lasek-Bal, Joanna Siuda, Karolina Piasecka-Stryczynska, Elena A. Parshina, Irina Poverennova, Byoung Joon Kim, Jeeyoung Oh, Alicia Martínez Piñeiro, Eduardo Morales, Long-Sun Ro, Jiann-Horng Yeh, Nai-Wen Tsai, Yuan-Ting Sun, Yi-Chung Lee, Chen-Chih Chung, Ayşe Nur YÜCEYAR, Ihsan Sukru Sengun, Aziz Shaibani, Waqar Waheed, Tuan Hoang Vu, Kelly G. Gwathmey, Ratna K. Bhavaraju-Sanka, Ali A Habib, Urvi Desai, Yessar Hussain, Nicholas S. Streicher, Ryan Drake, Marcelo Rugiero, Halina Navumava, Ruslan Yakubtsevich, Yury Holets, Marcelo V. Raffo, Eduardo Estephan, Fudong Shi, Anirudha Apte, Rahul Baviskar, Arvind N. N. Prabhu, Ruhal Kulkarni, Surya Prabha Turaga, Sanjay Ramteke, Genya Watanabe, Andrej Szczudlik, Małgorzata Zajda, Denis Korobko, Evgeny Evdoshenko, Zoya Goncharova, Yury Trinitatskiy, Klara Bakhtiyarova, Inna Smagina, Hsuah-Wen Hseuh, Olga Shulga, Oleksandr Doroshenko, Sergii Moskovko, Oleksandr Kalbus, George A. Small
|
JAMA Network
Verified
Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Number of Participants with Defined Components of Exacerbation during the MINT RCP eFigure 2. Annualized Exacerbation Rate eFigure 3. Swimmer Plots of Participants with Exacerbation during the MINT RCP eTable. Time to First Exacerbation by Week 26 (Full Analysis Set: MuSK+ Subpopulation) Supplement 3. Figure 1.
Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS
Abstract The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and when.
ALSUntangled #79: alpha-lipoic acid
Abstract Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It serves as an essential cofactor for enzymatic reactions in mitochondrial energy production, is a potent antioxidant and has anti-inflammatory effects, which are plausible mechanisms in slowing ALS progression. In ALS preclinical studies, ALA slowed motor function decline and improved survival.
Examining the evidence for IL-2 in amyotrophic lateral sclerosis
References 1. Miller, TM ∙ Cudkowicz, ME ∙ Genge, A ∙ et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS N Engl J Med. 2022; 387:1099-1110 2. Mitsumoto, H ∙ Brooks, BR ∙ Silani, V Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014; 13:1127-1138 3. Kiernan, MC ∙ Vucic, S ∙ Talbot, K ∙ et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis Nat Rev Neurol. 2021; 17:104-118 4.
Handling rescue therapy in myasthenia gravis clinical trials: why it matters and why you should care
Introduction Autoimmune myasthenia gravis (MG) is a disorder of neuromuscular transmission that leads to fatigable weakness of skeletal muscles, manifesting with weakness of extraocular, bulbar, neck, respiratory, and limb muscles.1, 2 Correspondingly, MG outcome measures aim to improve how patients feel and function.
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral Sclerosis
1 Introduction Amyotrophic lateral sclerosis (ALS) was characterized by Jean-Martin Charcot (1825–1893) as a progressive syndrome involving the combined degeneration of upper motor neurons of the corticospinal tract and lower motor neurons of the brain stem and anterior spinal cord. The resulting progressive skeletal muscle weakness strongly underpins the median survival of 30 months from the onset of symptoms (Westeneng et al. 2018).
Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis
INTRODUCTION Advances in our understanding of myasthenia gravis (MG) pathophysiology have aided the development of targeted treatment approaches with the potential to provide faster therapeutic benefit than mainstay treatments such as non-steroidal immunosuppressive therapies (NSISTs), without the problematic side effects associated with broad immunosuppression.
Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis
MB reports grants from the NIH (U01NS107027, U54NS092091) and the ALS Association (16-TACL-242) in support of this work. He is also an unpaid member of the Board of Trustees for the ALS Association. He has served as a consultant to Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche, Sanofi, Takeda, UCB, and UniQure. EAM reports grants from the NIH (U01NS107027, U54NS092091).
Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology - Nature Reviews Neurology
Correction to: Nature Reviews Neurology https://doi.org/10.1038/s41582-024-00961-z, published online 20 May 2024 In the version of the article initially published, Olga Uspenskaya’s name was misspelt (as Olga Uspenskay) and has now been amended in the HTML and PDF versions of the article. About this article Benatar, M., Wuu, J., Huey, E.D. et al. Publisher Correction: The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology - Nature Reviews Neurology
Abstract Increasing appreciation of the phenotypic and biological overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence for a pre-symptomatic stage of disease and observations that this stage of disease might not always be clinically silent, is challenging traditional views of these disorders.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Summary Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral sclerosis.
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
Discussion An increased number of therapeutics under development for MG in recent years has led to important observations about outcome measure training and performance in the clinical trial setting.
Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update
Results Six quality measures were approved for the final 2022 updated set (see the Table): ALS support services, DMP, nutrition and dysphagia screening, respiratory screening and appropriate intervention, multidisciplinary care plan, and patient care preferences quality measures. Full quality measurement specifications are available online at aan.com/practice/quality-measures/.
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
REQUIREMENTS You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
A roadmap to ALS prevention: strategies and priorities
Higher-risk groups for study and targeting of prevention efforts People with genetic risk factors Genetic risk factors for ALS broadly fall into three groups: (1) those that increase risk by a few percent, but because they are relatively common in the population, might represent a considerable risk in a person harbouring multiple such variants (eg, UNC13A single nucleotide variants); (2) those that increase risk more dramatically, by a few-fold (perhaps up to 300%), but are not sufficient to...
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis
Abstract Objective To explore the clinical efficacy and safety of subcutaneous (SC) rozanolixizumab, an anti-neonatal Fc receptor humanized monoclonal antibody, in patients with generalized myasthenia gravis (gMG). Methods In this phase 2a, randomized, double-blind, placebo-controlled, 2-period, multicenter trial (NCT03052751), patients were randomized (1:1) in period 1 (days 1–29) to 3 once-weekly (Q1W) SC infusions of rozanolixizumab 7 mg/kg or placebo.
International Consensus Guidance for Management of Myasthenia Gravis
Abstract Objective To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics.
International consensus guidance for management of myasthenia gravis
From the Beth Israel Deaconess Medical Center/Harvard Medical School (P.N.), Boston, MA; Department of Neurology (D.B.S., J.M.), Duke University Medical Center, Durham, NC; Department of Neurology (G.W.), Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY; Department of Neurology (M.B.), University of Miami, Miller School of Medicine.
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America http://orcid.org/0000-0003-2676-6031Joshua D Green1, Richard J Barohn2, Emanuela Bartoccion3, Michael Benatar4, Derrick Blackmore5, Vinay Chaudhry6, Manisha Chopra7, Andrea Corse6, Mazen M Dimachkie2, Amelia Evoli8, Julaine Florence9, Miriam Freimer10, James F Howard7, Theresa Jiwa11, Henry J Kaminski12, John T Kissel10, Wilma J Koopman13, Bernadette...
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS Michael Benatar, Lanyu Zhang, Lily Wang, Volkan Granit, Jeffrey Statland, Richard Barohn, Andrea Swenson, John Ravits, Carlayne Jackson, Ted M. Burns, Jaya Trivedi, Erik P. Pioro, James Caress, Jonathan Katz, Jacob L. McCauley, Rosa Rademakers, Andrea Malaspina, Lyle W. Ostrow, Joanne Wuu Neurology Jul 2020, 95 (1) e59-e69; DOI: 10.1212/WNL.0000000000009559
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS Michael Benatar, Lanyu Zhang, Lily Wang, Volkan Granit, Jeffrey Statland, Richard Barohn, Andrea Swenson, John Ravits, Carlayne Jackson, Ted M. Burns, Jaya Trivedi, Erik P. Pioro, James Caress, Jonathan Katz, Jacob L. McCauley, Rosa Rademakers, Andrea Malaspina, Lyle W. Ostrow, Joanne Wuu Neurology May 2020, 10.1212/WNL.0000000000009559; DOI: 10.1212/WNL.0000000000009559
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
ABSTRACT Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open‐label extension of REGAIN, evaluating eculizumab's long‐term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients.
Neurofilament light: A candidate biomarker of pre‐symptomatic ALS and phenoconversion
To evaluate neurofilament light (NfL) as a biomarker of the pre‐symptomatic phase of amyotrophic lateral sclerosis (ALS). The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at‐risk individuals observed both before and after the emergence of clinically manifest disease).
News from the National ALS Registry
The ALS Registry Act, passed in 2008, authorized establishment of a National ALS Registry with the goals of defining amyotrophic lateral sclerosis (ALS) incidence and prevalence, characterizing ALS patients' demographics, and examining risk factors.
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack